Want to see APVO full AI Analyst Report?
APVO Stock Chart & Stats
$4.39
-$0.18(-4.10%)
At close: 4:00 PM EDT
$4.39
-$0.18(-4.10%)
Day’s Range― - ―
52-Week Range$2.84 - $48.78
Previous Close$4.12
Volume37.98K
Average Volume (3M)11.64M
Market Cap
$5.16M
Enterprise Value-$5.57
Total Cash (Recent Filing)$9.80M
Total Debt (Recent Filing)$4.21M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-211.18
Shares Outstanding1,517,945
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-23.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation (AML)Robust Phase 1b AML results with high remission and clinical benefit rates plus favorable safety materially de-risk mipletamig vs standard venetoclax+azacitidine. Durable clinical differentiation increases chances of partnering, expedited development paths, and potential transplant-enabling outcomes for frail patients.
Platform/IP Expansion (Nectin-4 X PD-L1)A protected dual-targeting backbone creates a reusable engine for multiple modalities, raising long-term partnering and licensing optionality. Strengthened IP around a platform reduces single-asset dependence and supports multi-program pipeline expansion into solid tumors and radiopharma.
Strategic Radiopharmaceutical CollaborationThe Niowave tie-up gives Aptevo access to isotopes, shared development resources and aligned incentives via equity, lowering execution risk and capex needs. It diversifies modality exposure into targeted alpha therapies, a structurally growing segment, enhancing long-term pipeline resilience.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this scale forces continued reliance on external capital. That raises dilution and financing risk, limits the company's ability to internally fund multiple programs, and constrains tactical flexibility over the next several quarters.
No Recurring Revenue; Persistent LossesAs a clinical-stage biotech with no product sales, revenue depends on milestones and partnerships. Persistent net losses reduce runway and bargaining power in partnerships, increasing the probability of dilutive financings that can impair long-term shareholder returns.
Limited Scale / Resource ConstraintsA small team limits simultaneous program execution, internal capacity for IND-enabling/commercial preparations and rapid scale-up. Dependence on partners for development or manufacturing creates execution bottlenecks and heightens single-program concentration risk over 2-6 months.
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $2.84 and its highest was $48.78 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $5.16M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Overvalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 1,517,945 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Technical Analysis
Ownership Overview
0.44% Insiders
1.47% Mutual Funds
<0.01% Other Institutional Investors
97.25% Public Companies and
Individual Investors